168 related articles for article (PubMed ID: 21456051)
1. Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.
Saleh MI; Widness JA; Veng-Pedersen P
Biopharm Drug Dispos; 2011 Apr; 32(3):131-9. PubMed ID: 21456051
[TBL] [Abstract][Full Text] [Related]
2. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics.
Chapel SH; Veng-Pedersen P; Schmidt RL; Widness JA
Exp Hematol; 2001 Apr; 29(4):425-31. PubMed ID: 11301182
[TBL] [Abstract][Full Text] [Related]
3. Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.
Rosebraugh M; Widness JA; Veng-Pedersen P
Drug Metab Dispos; 2011 Jul; 39(7):1214-20. PubMed ID: 21460232
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.
Veng-Pedersen P; Chapel S; Al-Huniti NH; Schmidt RL; Sedars EM; Hohl RJ; Widness JA
Biopharm Drug Dispos; 2004 May; 25(4):149-56. PubMed ID: 15108217
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia.
Al-Huniti NH; Widness JA; Schmidt RL; Veng-Pedersen P
J Pharmacol Exp Ther; 2004 Jul; 310(1):202-8. PubMed ID: 14988424
[TBL] [Abstract][Full Text] [Related]
6. Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia.
Nalbant D; Saleh M; Goldman FD; Widness JA; Veng-Pedersen P
J Pharmacol Exp Ther; 2010 May; 333(2):528-32. PubMed ID: 20103588
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.
Saleh MI; Nalbant D; Widness JA; Veng-Pedersen P
Am J Physiol Regul Integr Comp Physiol; 2013 May; 304(9):R772-81. PubMed ID: 23485870
[TBL] [Abstract][Full Text] [Related]
8. Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.
Freise KJ; Widness JA; Segar JL; Schmidt RL; Veng-Pedersen P
Pharm Res; 2007 Sep; 24(9):1653-9. PubMed ID: 17457660
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin production rate in phlebotomy-induced acute anemia.
Al-Huniti NH; Widness JA; Schmidt RL; Veng-Pedersen P
Biopharm Drug Dispos; 2004 Dec; 25(9):389-97. PubMed ID: 15529399
[TBL] [Abstract][Full Text] [Related]
10. Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep.
El-Komy MH; Schmidt RL; Widness JA; Veng-Pedersen P
Biopharm Drug Dispos; 2011 Jul; 32(5):276-88. PubMed ID: 21678432
[TBL] [Abstract][Full Text] [Related]
11. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N; Jachimowicz E; Wojchowski DM
Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
[TBL] [Abstract][Full Text] [Related]
12. An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia.
Veng-Pedersen P; Chapel S; Schmidt RL; Al-Huniti NH; Cook RT; Widness JA
Pharm Res; 2002 Nov; 19(11):1630-5. PubMed ID: 12458668
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep.
Freise KJ; Widness JA; Schmidt RL; Veng-Pedersen P
J Pharmacokinet Pharmacodyn; 2007 Aug; 34(4):519-47. PubMed ID: 17516153
[TBL] [Abstract][Full Text] [Related]
14. Delayed hemoglobin switching and perinatal neocytolysis in mice with gain-of-function erythropoietin receptor.
Divoky V; Song J; Horvathova M; Kralova B; Votavova H; Prchal JT; Yoon D
J Mol Med (Berl); 2016 May; 94(5):597-608. PubMed ID: 26706855
[TBL] [Abstract][Full Text] [Related]
15. The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors.
Vukelic J; Dobrila-Dintinjana R; Jonjic N; Dekanic A; Ilijic V
Med Hypotheses; 2013 Dec; 81(6):1155-8. PubMed ID: 24134826
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants.
Freise KJ; Widness JA; Veng-Pedersen P
J Pharmacol Exp Ther; 2010 Jan; 332(1):229-37. PubMed ID: 19808699
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.
Neelakantan S; Widness JA; Schmidt RL; Veng-Pedersen P
Pediatr Int; 2009 Feb; 51(1):25-32. PubMed ID: 19371274
[TBL] [Abstract][Full Text] [Related]
18. Effect of Tumor Necrosis Factor-Alpha on Erythropoietin and Erythropoietin Receptor-Induced Erythroid Progenitor Cell Proliferation in β-Thalassemia/Hemoglobin E Patients.
Tanyong DI; Panichob P; Kheansaard W; Fucharoen S
Turk J Haematol; 2015 Dec; 32(4):304-10. PubMed ID: 26376749
[TBL] [Abstract][Full Text] [Related]
19. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S
Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis.
Al-Huniti NH; Widness JA; Schmidt RL; Veng-Pedersen P
J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):359-76. PubMed ID: 16284920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
